Developer docs
API playgroundTry for free, no card

Search company profiles

VVMF - Viral Vector Manufacturing Facility

Full company profile

uuid005kxzt

Namestring
VVMF - Viral Vector Manufacturing Facility
Websiteurl
vvmf.com.au
Company typeenum
Private
Founded yearstring
-
Descriptiontext

VVMF — Viral Vector Manufacturing Facility — is an Australian-headquartered manufacturing organization based in Westmead, New South Wales, founded in 2024 with a current headcount of approximately 40 employees. Based on the company name, it operates in the contract development and manufacturing (CDMO) segment of viral vector production, a critical input supply chain for gene therapy, cell therapy, and vaccine developers. The facility's location in Westmead, a major Sydney biomedical precinct anchored by Westmead Hospital and the Westmead Health and Innovation Precinct, suggests access to clinical research customers and workforce talent in the Australian life sciences cluster.

No substantive information about the company's core technology, production platforms, capacity, regulatory certifications (e.g., TGA GMP licensing), or specific product/service offerings is currently disclosed through public sources. The company's website (vvmf.com.au) presents only a loading/verification page with no accessible product, technology, or capability content. No pricing models, customer segments, partnerships, leadership team, or funding history are publicly available in the source data reviewed.

The business model cannot be characterized from available data. In the CDMO sector more broadly, revenue is typically generated through fee-for-service contracts, milestone-based development payments, and per-batch or per-dose manufacturing charges — but no such pricing detail, contract structure, or go-to-market signals are available for VVMF. The absence of disclosed customers, revenue figures, or strategic partnerships means the company's commercial traction cannot currently be assessed.

Short descriptiontext

VVMF is a newly established (2024) viral vector manufacturing facility based in Westmead, NSW, Australia, with approximately 40 employees. It operates in the contract manufacturing segment serving gene therapy and cell therapy developers, though no product, customer, or commercial details are publicly disclosed.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
Markets served

Serves global market

Keyword5 values
viral vector manufacturing, biopharmaceutical CDMO services, gene therapy manufacturing, cell therapy production, advanced therapy manufacturing
Industry1 code
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Manufacturing
Social media profiles1 record
Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

VVMF is a contract manufacturing facility that produces viral vectors for use in gene therapies, cell therapies, and vaccine development. The organization provides biotech and pharmaceutical clients with dedicated biomanufacturing capacity, process development support, and aseptic production capability at its Westmead, NSW site. Its output is physical viral vector material (drug substance and/or drug product) manufactured to pharmaceutical quality standards.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available. The source page displays a verification/loading screen with no accessible product content.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical CDMO with dedicated viral vector and cell-and-gene therapy manufacturing capacity across multiple sites. Directly comparable as the dominant incumbent VVMF would compete against in viral vector services.

TypeBroad incumbent
Description

Provides viral vector and cell therapy CDMO services (Cognate Bio, Retrogenix legacy) alongside broader preclinical and biologics capabilities. Comparable as a multi-service CDMO with material viral vector exposure.

TypeDirect peer
Description

US-based viral vector and lentiviral manufacturing CDMO focused on early-stage gene therapy developers. Most directly comparable pure-play peer: same service offering (viral vector manufacturing), targeting clinical-stage biotech customers.

TypeBroad incumbent
Description

Major CDMO with viral vector and gene therapy manufacturing services (formerly Paragon) and global biomanufacturing footprint. Comparable as a scaled incumbent offering overlapping viral vector capabilities.

TypeBroad incumbent
Description

Provides viral vector and cell therapy manufacturing services within WuXi AppTec's global CRDMO platform. Comparable as a large Asia-Pacific-adjacent CDMO with viral vector capabilities.

TypeBroad incumbent
Description

Global CDMO offering viral vector and cell therapy manufacturing services from European and US facilities. Comparable as a scaled CDMO with overlapping viral vector and gene therapy manufacturing capabilities.

TypeBroad incumbent
Description

Cell and gene therapy CDMO with substantial viral vector capacity (Center for Breakthrough Medicines). Comparable as a competing CDMO with overlapping viral vector CDMO services.

TypeBroad incumbent
Description

Through its Patheon and Brammer Bio acquisitions, Thermo Fisher offers viral vector development and manufacturing services. Comparable as a large diversified CDMO with overlapping viral vector CDMO offerings.

TypeDirect peer
Description

US-based viral vector manufacturing CDMO focused on AAV and lentiviral production for gene therapy developers. Highly comparable as a pure-play viral vector CDMO directly overlapping with VVMF's service scope.

TypeOthers
Description

Supplies bioprocess equipment, single-use technologies, and viral vector manufacturing solutions to CDMOs like VVMF. Comparable as a key enabler/supplier into the viral vector manufacturing infrastructure rather than a direct competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VVMF - Viral Vector Manufacturing Facility

Biopharmaceutical Contract Manufacturingvvmf.com.au

VVMF is a newly established (2024) viral vector manufacturing facility based in Westmead, NSW, Australia, with approximately 40 employees. It operates in the contract manufacturing segment serving gene therapy and cell therapy developers, though no product, customer, or commercial details are publicly disclosed.

What VVMF - Viral Vector Manufacturing Facility does

VVMF — Viral Vector Manufacturing Facility — is an Australian-headquartered manufacturing organization based in Westmead, New South Wales, founded in 2024 with a current headcount of approximately 40 employees. Based on the company name, it operates in the contract development and manufacturing (CDMO) segment of viral vector production, a critical input supply chain for gene therapy, cell therapy, and vaccine developers. The facility's location in Westmead, a major Sydney biomedical precinct anchored by Westmead Hospital and the Westmead Health and Innovation Precinct, suggests access to clinical research customers and workforce talent in the Australian life sciences cluster.

No substantive information about the company's core technology, production platforms, capacity, regulatory certifications (e.g., TGA GMP licensing), or specific product/service offerings is currently disclosed through public sources. The company's website (vvmf.com.au) presents only a loading/verification page with no accessible product, technology, or capability content. No pricing models, customer segments, partnerships, leadership team, or funding history are publicly available in the source data reviewed.

The business model cannot be characterized from available data. In the CDMO sector more broadly, revenue is typically generated through fee-for-service contracts, milestone-based development payments, and per-batch or per-dose manufacturing charges — but no such pricing detail, contract structure, or go-to-market signals are available for VVMF. The absence of disclosed customers, revenue figures, or strategic partnerships means the company's commercial traction cannot currently be assessed.

VVMF - Viral Vector Manufacturing Facility firmographics

Firmographics
Name
VVMF - Viral Vector Manufacturing Facility
Website
https://vvmf.com.au
Company type
Private
Headcount range
51–100 employees
Short description
VVMF is a newly established (2024) viral vector manufacturing facility based in Westmead, NSW, Australia, with approximately 40 employees. It operates in the contract manufacturing segment serving gene therapy and cell therapy developers, though no product, customer, or commercial details are publicly disclosed.
Ownership category
akta.pro rank

VVMF - Viral Vector Manufacturing Facility industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)

Keywords

  • Viral vector manufacturing
  • Biopharmaceutical CDMO services
  • Gene therapy manufacturing
  • Cell therapy production
  • Advanced therapy manufacturing

VVMF - Viral Vector Manufacturing Facility business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Others

VVMF - Viral Vector Manufacturing Facility product offering

Product offering

Core offering

VVMF is a contract manufacturing facility that produces viral vectors for use in gene therapies, cell therapies, and vaccine development. The organization provides biotech and pharmaceutical clients with dedicated biomanufacturing capacity, process development support, and aseptic production capability at its Westmead, NSW site. Its output is physical viral vector material (drug substance and/or drug product) manufactured to pharmaceutical quality standards.

Product overview

No product information available. The source page displays a verification/loading screen with no accessible product content.

Differentiator

Problem solved

Functional benefit

Companies that use VVMF - Viral Vector Manufacturing Facility

Customer profile

Ideal customer profiles1 record

VVMF - Viral Vector Manufacturing Facility technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

VVMF - Viral Vector Manufacturing Facility partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

VVMF - Viral Vector Manufacturing Facility competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global pharmaceutical CDMO with dedicated viral vector and cell-and-gene therapy manufacturing capacity across multiple sites. Directly comparable as the dominant incumbent VVMF would compete against in viral vector services.
  • Charles River Laboratories: Provides viral vector and cell therapy CDMO services (Cognate Bio, Retrogenix legacy) alongside broader preclinical and biologics capabilities. Comparable as a multi-service CDMO with material viral vector exposure.
  • Catalent (Novo Holdings): Major CDMO with viral vector and gene therapy manufacturing services (formerly Paragon) and global biomanufacturing footprint. Comparable as a scaled incumbent offering overlapping viral vector capabilities.
  • WuXi Advanced Therapies (WuXi AppTec): Provides viral vector and cell therapy manufacturing services within WuXi AppTec's global CRDMO platform. Comparable as a large Asia-Pacific-adjacent CDMO with viral vector capabilities.
  • AGC Biologics: Global CDMO offering viral vector and cell therapy manufacturing services from European and US facilities. Comparable as a scaled CDMO with overlapping viral vector and gene therapy manufacturing capabilities.
  • SK pharmteco / Center for Breakthrough Medicines: Cell and gene therapy CDMO with substantial viral vector capacity (Center for Breakthrough Medicines). Comparable as a competing CDMO with overlapping viral vector CDMO services.
  • Thermo Fisher Scientific (Patheon / Brammer Bio): Through its Patheon and Brammer Bio acquisitions, Thermo Fisher offers viral vector development and manufacturing services. Comparable as a large diversified CDMO with overlapping viral vector CDMO offerings.

Direct peers

  • Genezen: US-based viral vector and lentiviral manufacturing CDMO focused on early-stage gene therapy developers. Most directly comparable pure-play peer: same service offering (viral vector manufacturing), targeting clinical-stage biotech customers.
  • VintaBio: US-based viral vector manufacturing CDMO focused on AAV and lentiviral production for gene therapy developers. Highly comparable as a pure-play viral vector CDMO directly overlapping with VVMF's service scope.

Others

  • Cytiva (Danaher): Supplies bioprocess equipment, single-use technologies, and viral vector manufacturing solutions to CDMOs like VVMF. Comparable as a key enabler/supplier into the viral vector manufacturing infrastructure rather than a direct competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

VVMF - Viral Vector Manufacturing Facility social profiles

Digital presence

VVMF - Viral Vector Manufacturing Facility financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VVMF - Viral Vector Manufacturing Facility leadership team

Management profile

Number of profiles

VVMF - Viral Vector Manufacturing Facility funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VVMF - Viral Vector Manufacturing Facility M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VVMF - Viral Vector Manufacturing Facility

What does VVMF - Viral Vector Manufacturing Facility do?

VVMF is a contract manufacturing facility that produces viral vectors for use in gene therapies, cell therapies, and vaccine development. The organization provides biotech and pharmaceutical clients with dedicated biomanufacturing capacity, process development support, and aseptic production capability at its Westmead, NSW site. Its output is physical viral vector material (drug substance and/or drug product) manufactured to pharmaceutical quality standards.

When was VVMF - Viral Vector Manufacturing Facility founded?

VVMF - Viral Vector Manufacturing Facility was founded in -1. It employs 51 to 100 people.

Who are VVMF - Viral Vector Manufacturing Facility's main competitors?

Broad incumbents on record are Lonza Group, Charles River Laboratories, Catalent (Novo Holdings), WuXi Advanced Therapies (WuXi AppTec), AGC Biologics, SK pharmteco / Center for Breakthrough Medicines and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are Genezen and VintaBio. Cytiva (Danaher) is listed as an others.

Does VVMF - Viral Vector Manufacturing Facility have an API?

No public API is recorded for VVMF - Viral Vector Manufacturing Facility.

What industry is VVMF - Viral Vector Manufacturing Facility in?

VVMF - Viral Vector Manufacturing Facility's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireOXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platformsOXB entered a licensing and option agreement with VVMF, granting a worldwide, non-exclusive license to its AAV and LV platforms for five years. OXB will receive a low single-digit million licence fee and future payments. The deal aims to accelerate VVMF's manufacturing capabilities and position Australia as a regional hub for cell and gene therapy.Life Science Company NewsNew Australian collaboration to advance gene and cell therapy sectorAustralia-based contract development and manufacturing organizations Viral Vector Manufacturing Facility (VVMF) and Cell Therapies have signed a Memorandum of Understanding (MoU) to collaborate on advancing the onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs). This partnership aims to enhance access to ATMPs for both Australian and international patients through clinical trials.BiomelbourneChimeric Therapeutics partners with Viral Vector Manufacturing Facility to boost GMP viral vector productionChimeric Therapeutics has signed a Letter of Intent with Viral Vector Manufacturing Facility Pty Ltd to establish a partnership aimed at the GMP production of Lentiviral vectors in Australia. This collaboration is expected to enhance the supply chain for Chimeric's CAR-T therapy programmes and bolster Australia's advanced therapy capabilities. The agreement is seen as a significant milestone for the country's advanced manufacturing sector and aims to create high-value jobs in Western Sydney.